Breast Biopsy Market Report 2024

This Breast Biopsy market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The breast biopsy market size has grown strongly in recent years. It will grow from $1.33 billion in 2023 to $1.42 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The growth during the historic period can be attributed to the increasing prevalence of breast cancer, the aging population, expanding awareness programs, rising healthcare expenditure, and a shift toward outpatient and ambulatory settings.

The breast biopsy market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The growth during the forecast period can be attributed to advancements in healthcare infrastructure, the expansion of personalized medicine, increased healthcare access in developing regions, supportive regulatory and reimbursement policies, and the rise of telemedicine and remote diagnostics. Key trends include the integration of robotics in biopsy procedures, growth in home-based biopsy kits, the increasing importance of genomic biopsies, a focus on patient-centered care models, the use of blockchain for data security, and an emphasis on post-biopsy monitoring tools.

The increasing prevalence of breast cancer is expected to drive the growth of the breast biopsy market in the future. Breast cancer is a malignant tumor that originates in breast tissue cells and can spread to other parts of the body if not treated promptly. Contributing factors to the rise in breast cancer prevalence include longer life expectancy, improved detection methods, and heightened awareness of the disease. A breast biopsy involves obtaining tissue samples from suspicious areas in the breast to diagnose and assess the characteristics of breast cancer. For example, in January 2023, the American Cancer Society reported that the number of new invasive breast cancer cases among American women increased from approximately 281,550 in 2021 to 297,790 in 2023. Consequently, the growing prevalence of breast cancer is fueling the expansion of the breast biopsy market.

Major companies in the breast biopsy market are focusing on developing innovative solutions, such as vacuum-assisted breast biopsy systems, to improve care for patients with benign lesions. A vacuum-assisted breast biopsy system is a medical device that uses suction to obtain multiple tissue samples from a suspicious breast area through a single needle insertion. For example, in August 2022, Devicor Medical Products, Inc., a US-based medical device company, introduced the Mammotome Revolve EX Dual Vacuum-Assisted Breast Biopsy System. This system features a dual vacuum mechanism for enhanced tissue collection, providing high-volume sampling and greater accuracy. Its ergonomic design includes a rotating probe for better maneuverability and a single insertion process to reduce patient discomfort. Additionally, the system integrates real-time imaging for precise targeting and efficient biopsy procedures.

In May 2024, Lunit Inc., a South Korea-based medical software company, acquired Volpara Health Technologies Ltd. for an undisclosed amount. This acquisition will enable Lunit Inc. to expand its portfolio with advanced breast imaging and analysis technologies, thereby enhancing its capabilities in early cancer detection. Volpara Health Technologies Ltd., based in New Zealand, is a provider of breast biopsy solutions.

Major companies operating in the breast biopsy market are Medtronic PLC, Siemens Healthineers AG, Fujifilm Holdings Corporation, Becton Dickinson and Company (BD), Koninklijke Philips, GE HealthCare Technologies Inc., Hologic Inc., The Cooper Companies Inc., Merit Medical Systems, Argon Medical Devices, Canon Medical Systems Corporation, Devicor Medical Products Inc., Mermaid Medical Group, Planmed Oy, Menarini-Silicon Biosystems, Seno Medical Instruments Inc., Surgical Innovations Group, Sterylab Srl, Dilon Technologies Inc., INRAD Inc., Promaxo Inc.

North America was the largest region in the breast biopsy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the breast biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A breast biopsy is a medical procedure in which a small sample of breast tissue is removed and examined under a microscope to determine if it is cancerous or benign. It is typically performed when a lump or abnormality is detected in the breast through imaging tests or physical exams. The biopsy can be done using various methods, such as needle biopsy or surgical biopsy, often guided by imaging techniques such as ultrasound, and mammography.

The main types of breast biopsy are biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and others. Biopsy needles are specialized medical tools used to extract tissue samples from the breast for examination. The image-guided technologies are magnetic resonance imaging (MRI)-guided breast biopsy, ultrasound-guided breast biopsy, mammography-guided stereotactic biopsy, computed tomography (CT)-guided biopsy, and others, and the procedures are needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. The applications include hospitals, clinics, diagnostic centers, and others.

The breast biopsy market research report is one of a series of new reports that provides breast biopsy market statistics, including breast biopsy industry global market size, regional shares, competitors with a breast biopsy market share, detailed breast biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the breast biopsy industry. This breast biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The breast biopsy market consists of revenues earned by providing services such as biopsy procedures, consultations, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The breast biopsy market also includes sales of biodegradable tissue markers, and semi-automated and fully automated biopsy needles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.